Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Reports Fourth Quarter and Year End 2013 Results
SOLANA BEACH, Calif. , March 25, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013 .
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results
SAN DIEGO , March 10, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Fourth Quarter of 2013 on Tuesday, March 25, 2014 , after
View HTML
Toggle Summary Evoke Pharma to Present at 26th Annual ROTH Conference
SAN DIEGO , March 4, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer , R.Ph., will be presenting at the 26 th Annual
View HTML
Toggle Summary Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics
SAN DIEGO , Jan. 22, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing
View HTML
Toggle Summary Evoke Pharma to Present at Biotech Showcase(TM) 2014
SAN DIEGO , Jan. 7, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer is scheduled to present at Biotech Showcase™
View HTML
Toggle Summary Evoke Pharma Strengthens Executive Team With Appointments of Chief Medical Officer and Senior Director of Clinical Operations
Experienced Clinical Executives to Drive Phase 3 Trial of EVK-001 for Gastroparesis
View HTML
Toggle Summary Evoke Pharma Selects SynteractHCR as Contract Research Organization for Phase 3 Trial of EVK-001 for Gastroparesis
SAN DIEGO , Nov. 26, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the selection of SynteractHCR, Inc. to serve as its primary contract research organization ("CRO") for its
View HTML
Toggle Summary Evoke Pharma Reports Third Quarter 2013 Results
SAN DIEGO , Nov. 13, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2013 .
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2013 Financial Results
SAN DIEGO , Nov. 5, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Third Quarter of 2013 on Wednesday, November 13, 2013 , after
View HTML
Toggle Summary Evoke Pharma Announces Full Exercise of Underwriters' Over-Allotment Option
SAN DIEGO , Oct. 3, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an
View HTML